Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants (PNIRS in VLBWI)
Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants: a Pilot Study
This study will look at whether a monitoring method called near-infrared spectroscopy (NIRS), can help assess lung disease in premature babies.
The main aim of this study is to describe lung oxygen levels measured by NIRS in premature babies with respiratory distress syndrome (RDS) during the first 72 hours after birth. The study will include babies born at or before 32 weeks of pregnancy who need continuous positive airway pressure (CPAP) for RDS. The study will also assess whether these lung oxygen measurements can help predict which babies will need surfactant treatment, and whether they can predict which babies may need more than one dose of surfactant.
The study will also compare lung NIRS measurements with other ways of assessing breathing problems, including lung ultrasound scores and oxygen-related measurements. In addition, the researchers will compare lung oxygen measurements with brain oxygen measurements. They will also look at whether surfactant treatment changes oxygen levels in the lungs and brain. Information from routine vital signs, such as heart rate, breathing rate, and oxygen saturation, will also be studied to see whether these measurements can help predict the need for surfactant.
Added to this researchers will look at the hemodynamics of surfactant administration by seeing how the heart and blood vessels react to surfactant administration
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Aim: To determine pulmonary regional oxygen saturation (prSO2) in preterm infants (≤32 weeks) with respiratory distress syndrome (RDS) requiring continuous positive airway pressure (CPAP) with or without surfactant replacement therapy (SRT)
Objectives:
Primary: Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life. Secondary: (1) Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS, (2) Evaluate the ability of prSO2 to predict the need for repeat surfactant administration in preterm infants with RDS, (3) Determine correlation between prSO2, lung ultrasound (LUS) scores and oxygenation indices.
Tertiary: (1) Determine the correlation between prSO2 and cerebral oxygenation (crSO2), (2) Determine the effect of surfactant administration on prSO2 and crSO2, (3) longitudinal analyses of vital signs (HR, SpO2, NIRS, oxygenation indices) to predict SRT, (4) determine the hemodynamic effects of SRT (longitudinal correlation of NIRS, haemodynamic parameters)
This will be an investigator-initiated, prospective, observational trial.
Preterm infants born at a gestational age ≤ 32 weeks will be recruited from a single neonatal center, Tygerberg Hospital, Cape Town, South Africa.
All preterm infants ≤ 32 weeks and/ or ≤1800g will be eligible for enrollment
Study Procedures
Recruitment and enrollment processes Infants will be screened within the first 3 hours after birth. Infants meeting enrollment criteria will be placed on study monitoring devices upon arrival in the neonatal unit, if meeting eligibility criteria.
Randomization/ blinding No randomization will occur in this study. Blinding is not possible due to visible monitoring equipment. Treating clinicians will however be directed not to use the monitors for any decision-making regarding patient management.
Monitoring Devices
-
Near-infrared spectroscopy will be performed using INVOS 5100c (Medtronics, Minneapolis, MN, USA) with 2 transducers, will be used that allows monitoring of 4 regions of interest. In this study 3 regional saturations will be monitored - pulmonary (left and right) and cerebral
- Pulmonary NIRS - Pulmonary sensors will be placed in a horizontal position at the 4th intercostal space area (nipple line) on the left and right hemithorax
- Cerebral NIRS - Cerebral sensor will be placed on the right of the forehead
-
Vital sign monitoring: Synchronized vital signs (heart rate (HR), respiratory rate (RR), peripheral oxygen saturation (SpO2) (Nellcor) will be monitored using a multi-parameter monitor (Mindray UMEC15, Shenzhen, China).
-
Non-invasive cardiac output monitoring: Haemodynamic monitoring will occur using the ICON Core from Osypka Medical. This provides non-invasive monitoring of numerous haemodynamic parameters, including cardiac output, stroke volume, systemic vascular resistance, cardiac contractility and thoracic fluid content. ICON sensors will be placed in standard positions on the forehead, neck arm and leg for monitoring.
Intervention procedures
1. Ultrasound:
- Lung ultrasound (LUS) will be performed after placement of the NIRS (within the first 6 hours of life) and daily. LUS will also be performed prior to any SRT. alculated. Video-clips will be stored and reviewed by blinded co-investigators.
- Cranial ultrasound (CUS) will be performed on day 1,2 and 3 to monitor for any intraventricular haemorrhage as well as to measure cerebral blood flow velocities, which may affect crSO2 values.
- Point-of-care echocardiography (POC-echo) will be performed to determine cardiac function, cardiac output, and the presence of a patent ductus arteriosus, size, flow velocity and pattern, which may affect prSO2 and crSO2 values. Standard echocardiography techniques will be used and will be performed daily on day 1,2 and 3 of life.
Trial duration
The trial will start enrolling 1 November 2026 or when all procedures have been completed. Trial will be completed when 100 participants have been recruited.
Discontinuation of study intervention
Monitoring of the infant will stop, and sensors will be removed if:
- Requested by mother
- Requested by treating clinician
- Thoracic intervention required (e.g. intercostal drainage for pneumothorax)
- Surgery required (e.g. laparotomy for focal intestinal perforation)
- Sensors interfere with medical management
Withdrawal from study
At any time point the mother or treating clinician may request withdrawal of the infant from the study, for any reason, whether for personal choice (by the mother), safety considerations or administrative reasons. Monitoring of the infant will be stopped immediately, and no further data will be collected. However, the infant will remain in the study for data analyses and outcome and clinical measure collection, unless the mother specifically requests that their infant's data not be included. Withdrawal of the infant from the study, irrespective of reason, will not influence the continued management of the infant and they will continue to receive management as per protocols in the institution.
Duration of study participation
Study participation for each infant is:
- Initiated within the first 3 hours of life
- Monitoring until 72 hours after birth
- Follow up from 72 hours until final discharge from hospital or in-hospital death.
Infants who are transferred to other institutions will be followed up for length of stay as well as neonatal respiratory complications (length of respiratory support, bronchopulmonary dysplasia, death)
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Lizelle Van Wyk, PhD
- Numer telefonu: +27219389506
- E-mail: lizelle@sun.ac.za
Lokalizacje studiów
-
-
-
Cape Town, Afryka Południowa, 7530
- Rekrutacyjny
- Tygerberg Hospital
-
Kontakt:
- Lizelle Van Wyk, PhD
- Numer telefonu: 6058 +27219384911
- E-mail: lizelle@sun.ac.za
-
Kontakt:
- Pierre Goussard, PhD
- Numer telefonu: +27219389506
- E-mail: pgouss@sun.ac.za
-
Główny śledczy:
- Lizelle Van Wyk, PhD
-
Pod-śledczy:
- Pierre Goussard, PhD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
All preterm infants 27-32 weeks born at Tygerberg Hospital, Cape Town, South Africa will be elligible for enrollment
Opis
Inclusion Criteria:
- Preterm infant ≤ 32 weeks gestational age and/ or birth weight ≤ 1800g
- Infant diagnosed with respiratory distress syndrome requiring CPAP after birth
- Infant born at the research institution
Exclusion Criteria:
- Infants ≤ 26 weeks gestational age or <750g
- Infants with other causes of respiratory distress
- Infants with antenatal or postnatally diagnosed structural pulmonary abnormalities
- Infants with known or suspected chromosomal abnormalities
- Infants with other congenital structural abnormalities that may require surgery in the first 72 hours after birth
- Infants with known or suspected congenital infections including congenital syphilis, cytomegalovirus or toxoplasmosis
- Infants intubated after birth or requiring intubation and invasive ventilation immediately after birth
- Infants with a 5-minute Apgar ≤ 5
- Instillation of surfactant prior to enrollment
- Infants not expected to survive the first 72 hours after birth
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Liczba grup / kohort
Kohorty i interwencje
Grupa / KohortaGrupa / Kohorta |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
CPAP only
Infants receiving CPAP only |
Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position |
|
SRT
Infants receiving CPAP plus surfactant |
Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
PRSO2 values
Ramy czasowe: 72 hours
|
Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life |
72 hours
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
SRT prediction
Ramy czasowe: 72 hours
|
Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS |
72 hours
|
|
Compare prSo2 & lung ultrasound between groups
Ramy czasowe: 72 hours
|
Determine correlation between prSO2 and lung ultrasound (LUS) scores between groups |
72 hours
|
|
Compare prSo2 & OSI between groups
Ramy czasowe: 72 hours
|
Determine correlation between prSO2 and OSI between groups |
72 hours
|
|
Compare prSo2 & SOPI between groups
Ramy czasowe: 72hrs
|
Determine correlation between prSO2 and SOPI between groups |
72hrs
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
PRSO2/CUS
Ramy czasowe: 72hours
|
Determine the correlation between prSO2 and cerebral oxygenation (crSO2) between groups |
72hours
|
|
Longitudinal analysis SOPI
Ramy czasowe: 72 hours
|
longitudinal comparison of SOPI between groups |
72 hours
|
|
Longitudinal OSI
Ramy czasowe: 72 hours
|
longitudinal comparison of OSI between groups |
72 hours
|
|
Longitudinal thoracic fluid content (TFC)
Ramy czasowe: 72 hours
|
longitudinal comparison of TFC between groups |
72 hours
|
|
Longitudinal CI
Ramy czasowe: 72 hours
|
longitudinal comparison of cardiac index between groups |
72 hours
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Publikacje i pomocne linki
Publikacje ogólne
- Dani C, Miselli F, Zini T, Scarponi D, Luzzati M, Sarcina D, Fusco M, Dianori F, Berardi A. Measurement of lung oxygenation by near-infrared spectroscopy in preterm infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 2024 Jun;59(6):1631-1637. doi: 10.1002/ppul.26955. Epub 2024 Mar 5.
- Ozdemir FE, Alan S, Aliefendioglu D. The diagnostic value of pulmonary near-infrared spectroscopy in the early distinction of neonatal pneumonia from transient tachypnea of the newborn. Pediatr Pulmonol. 2023 Nov;58(11):3271-3278. doi: 10.1002/ppul.26656. Epub 2023 Aug 30.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 32886
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Patient data, as per SUN HREC guidelines, can only be shared upon an agreed upon data sharing agreement
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .